Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 2, 23 | -0.37 Increased by +36.21% | -0.52 Increased by +28.85% |
| Aug 2, 23 | -0.53 Decreased by -1.92% | -0.59 Increased by +10.17% |
| May 3, 23 | -0.68 Decreased by -21.43% | -0.62 Decreased by -9.68% |
| Feb 28, 23 | -0.66 Decreased by -22.22% | -0.7 Increased by +5.71% |
| Nov 2, 22 | -0.58 Decreased by -1.75% | -0.64 Increased by +9.38% |
| Aug 9, 22 | -0.52 Increased by +1.89% | -0.61 Increased by +14.75% |
| May 4, 22 | -0.56 Decreased by -124% | -0.58 Increased by +3.45% |
| Feb 23, 22 | -0.54 Decreased by -1.89% | -0.6 Increased by +10% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 43 K Decreased by -12.24% | -61.31 M Increased by +25.36% | Decreased by -142.59 K% Increased by +14.94% |
| Jun 30, 23 | 44 K Decreased by -48.84% | -77.99 M Decreased by -4.72% | Decreased by -177.25 K% Decreased by -104.69% |
| Mar 31, 23 | 52 K Decreased by -14.75% | -98.34 M Decreased by -23.37% | Decreased by -189.11 K% Decreased by -44.73% |
| Dec 31, 22 | 47 K Decreased by -7.84% | -93.32 M Decreased by -24.65% | Decreased by -198.55 K% Decreased by -35.25% |
| Sep 30, 22 | 49 K Increased by 0% | -82.15 M Decreased by -5.06% | Decreased by -167.64 K% Decreased by -5.06% |
| Jun 30, 22 | 86 K Increased by +95.45% | -74.47 M Decreased by -4.98% | Decreased by -86.6 K% Increased by +46.29% |
| Mar 31, 22 | 61 K Decreased by -99.84% | -79.71 M Decreased by -141.43% | Decreased by -130.67 K% Decreased by -151.66 K% |
| Dec 31, 21 | 51 K Increased by +N/A% | -74.87 M Decreased by -9.18% | Decreased by -146.8 K% Decreased by N/A% |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.